9 recruiting, 3 completed, 2 active not recruiting, 1 not yet recruiting. 10 Phase 1, 7 Phase 2, 1 Early Phase 1.
Follow Plasmablastic Lymphoma: new trials by email Literature Review of Plasmablastic Lymphoma trials Research Report on Plasmablastic Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-10-28 |
| Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma Biospecimen Collection, Computed Tomography, Positron Emission Tomography - Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2027-03-26 | 2026-10-20 |
| HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV Elranatamab (Elra) - Plasmablastic Lymphoma, HIV | Phase 1 | Recruiting | University of Illinois at Chicago | 17 | 2026-10-21 | 2026-10-26 |
| RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies Allogeneic CAR-T - Relapsed or Refractory B-cell Hematologic Malignancies, B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 1 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 27 | 2025-08-01 | 2025-08-13 |
| Study on Plasmablastic Lymphoma Patients Plasmablastic Lymphoma | Recruiting | Fondazione Italiana Linfomi - ETS | 200 | 2025-02-14 | 2026-08-19 | |
| Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas Vincristine, Prednisone, Doxorubicin - Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 25 | 2023-06-27 | 2026-08-25 |
| Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers Biospecimen Collection - Anal Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm | Recruiting | AIDS Malignancy Consortium | 200 | 2023-05-10 | 2026-06-01 | |
| Study of SGR-1505 in Mature B-Cell Neoplasms SGR-1505 - Mature B-Cell Neoplasm, Non Hodgkin Lymphoma | Phase 1 | Recruiting | Schrödinger, Inc. | 98 | 2023-04-10 | 2026-02-13 |
| Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. Daratumumab, Bortezomib, Dexamethasone - Plasmablastic Lymphoma | Phase 2 | Recruiting | Fondazione Italiana Linfomi - ETS | 28 | 2022-07-11 | 2026-09-09 |
| Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma Belantamab Mafodotin - Relapsed Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma | Phase 2 | Terminated | Jacob Soumerai, MD | 10 | 2021-07-01 | 2026-03-13 |
| A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma Cyclophosphamide, Daratumumab, Doxorubicin - Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma | Early Phase 1 | Recruiting | AIDS Malignancy Consortium | 15 | 2021-05-24 | 2026-10-28 |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Nivolumab, Varlilumab - ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2018-12-21 | 2026-10-26 |
| Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies XmAb13676 - B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Completed | Xencor, Inc. | 154 | 2016-10-01 | 2024-11-13 |
| Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | AIDS Malignancy Consortium | 11 | 2016-06-23 | 2026-05-18 |
| Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride - Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma | Phase 1 / Phase 2 | Unknown | Northwestern University | 38 | 2015-10-28 | 2022-02-21 |
| Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide - AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 107 | 2010-10-06 | 2023-11-21 |
| Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma EPOCH-R, EPOCH-RR - Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive | Phase 2 | Completed | National Cancer Institute (NCI) | 194 | 2010-03-25 | 2023-04-27 |
Burkitt Lymphoma (8) · Lymphoma, Large B-Cell, Diffuse (7) · Lymphoma, Primary Effusion (5) · HIV Infections (4) · Lymphoma, B-Cell (4) · Lymphoma, Follicular (4) · Lymphoma, Non-Hodgkin (4) · Lymphoma, Mantle-Cell (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphomatoid Granulomatosis (2) · Pyloric Stenosis, Hypertrophic (2) · Recurrence (2)
Hemic and Lymphatic Diseases (17) · Immune System Diseases (17) · Immunoproliferative Disorders (17) · Lymphatic Diseases (17) · Lymphoproliferative Disorders (17) · Neoplasms (17) · Neoplasms by Histologic Type (17) · Lymphoma (15) · Lymphoma, B-Cell (13) · Lymphoma, Non-Hodgkin (13) · Infections (10) · Lymphoma, Large B-Cell, Diffuse (10) · Virus Diseases (10) · DNA Virus Infections (9) · Herpesviridae Infections (9)
Cyclophosphamide (6) · Doxorubicin (6) · Etoposide (6) · Prednisone (6) · Vincristine (6) · Rituximab (5) · deltacortene (4) · prednylidene (4) · CT-P10 (2) · Cytarabine (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · daratumumab (2) · Biopsy (1) · Bortezomib (1)
National Cancer Institute (NCI) (6) · AIDS Malignancy Consortium (3) · Fondazione Italiana Linfomi - ETS (2) · Jacob Soumerai, MD (1) · Northwestern University (1) · Schrödinger, Inc. (1) · The First Affiliated Hospital with Nanjing Medical University (1) · University of Illinois at Chicago (1) · Xencor, Inc. (1)
United States (14) · Italy (3) · France (2) · China (1) · Moldova (1) · Poland (1) · Romania (1) · South Korea (1) · Spain (1) · Ukraine (1) · United Kingdom (1)
Alessia Castellino, MD (1) · Ariela Noy, MD (1) · Barbara Pro, MD (1) · Chet Bohac, PharmD, MD, MSc (1) · Emanuele Ravano, MD (1) · Frank G Basile, M.D. (1) · Jacob Soumerai, MD (1) · James Godfrey (1) · Jeff Bethony (1) · Juan C Ramos (1) · Lei Fan (1) · Mark J Roschewski, M.D. (1) · Mehrdad Abedi (1) · Paul Rubinstein, MD (1)
PMID 30501868, PMID 32430507, PMID 32453640, PMID 38237077
UM1CA121947 (4), P30CA060553 (1), U01CA121947 (1), UM1CA186686 (1), UM1CA186709 (1), UM1CA186717 (1)